Display options
Cite
Artemniak-Wojtowicz D, Witkowska-Sędek E, Borowiec A, et al. Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy. Cent Eur J Immunol. 2019;44(2):132-137doi: 10.5114/ceji.2019.87063.
Artemniak-Wojtowicz, D., Witkowska-Sędek, E., Borowiec, A., & Pyrżak, B. (2019). Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy. Central-European journal of immunology, 44(2), 132-137. https://doi.org/10.5114/ceji.2019.87063
Artemniak-Wojtowicz, Dorota, et al. "Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy." Central-European journal of immunology vol. 44,2 (2019): 132-137. doi: https://doi.org/10.5114/ceji.2019.87063
Artemniak-Wojtowicz D, Witkowska-Sędek E, Borowiec A, Pyrżak B. Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy. Cent Eur J Immunol. 2019;44(2):132-137. doi: 10.5114/ceji.2019.87063. Epub 2019 Jul 30. PMID: 31530982; PMCID: PMC6745550.
Copy Download .nbib Format: NLM
Share it on

Cent Eur J Immunol. 2019;44(2):132-137. doi: 10.5114/ceji.2019.87063. Epub 2019 Jul 30.

Peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease at baseline and after the initiation of antithyroid drug therapy.

Central-European journal of immunology

Dorota Artemniak-Wojtowicz, Ewelina Witkowska-Sędek, Ada Borowiec, Beata Pyrżak

Affiliations

  1. Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

PMID: 31530982 PMCID: PMC6745550 DOI: 10.5114/ceji.2019.87063

Abstract

AIM OF THE STUDY: Assessment of the peripheral blood picture and aminotransferase activity in children with newly diagnosed Graves' disease (GD) at baseline and 4-6 weeks after the initiation of antithyroid drug (ATD) therapy.

MATERIAL AND METHODS: Data of 59 children were assessed retrospectively. Baseline analysis included concentrations of thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), TSH receptor antibodies (TSH-R Ab), complete blood cell count (CBC), aspartate (AST) and alanine aminotransferase (ALT) activity. Reassessment of CBC and aminotransferase activity was performed 4-6 weeks after the initiation of ATD therapy.

RESULTS: Significant decreases in the neutrophil count, MCV, haemoglobin (Hgb), red blood cell (RBC) count, white blood cell (WBC) count and platelet (PLT) count were found in 37.3%, 32.2%, 22%, 13.6%, 8.5% and 5% of untreated patients, respectively. Increased baseline ALT and AST activity was observed in 44% and 32.2% of children, respectively. Initiation of ATD therapy led to significant changes in Hgb, RBC and PLT count, RDW and ALT activity. Negative associations between TSH-R Ab, TSH and MCV were found. ALT and AST activity were negatively related to baseline TSH levels. ALT activity was also associated with baseline fT4 and fT3.

CONCLUSIONS: The incidence of haematopoiesis and liver abnormalities in GD children seems to be similar to that reported in adult patients. The most common alterations are changes in neutrophil count, RBC parameters and ALT activity. The initiation of ATD therapy usually leads to significant improvement in those parameters.

Keywords: autoimmunity; children; hyperthyroidism; liver function; peripheral blood cells

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. J Clin Gastroenterol. 1999 Dec;29(4):318-21 - PubMed
  2. Arch Intern Med. 2000 Mar 13;160(5):661-6 - PubMed
  3. N Engl J Med. 2000 Oct 26;343(17):1236-48 - PubMed
  4. Endocr Pract. 2000 Sep-Oct;6(5):367-9 - PubMed
  5. QJM. 2002 Sep;95(9):559-69 - PubMed
  6. Clin Lab Haematol. 2002 Dec;24(6):385-7 - PubMed
  7. J Clin Endocrinol Metab. 2003 Aug;88(8):3474-81 - PubMed
  8. J Clin Gastroenterol. 1992 Apr;14(3):240-4 - PubMed
  9. N Engl J Med. 2005 Mar 3;352(9):905-17 - PubMed
  10. J Clin Endocrinol Metab. 2007 Jun;92(6):2157-62 - PubMed
  11. Clin Endocrinol (Oxf). 2008 Mar;68(3):481-4 - PubMed
  12. Clin Endocrinol (Oxf). 2009 May;70(5):781-7 - PubMed
  13. Int J Immunogenet. 2009 Apr;36(2):85-96 - PubMed
  14. N Engl J Med. 2009 Apr 9;360(15):1574-5 - PubMed
  15. Eur J Endocrinol. 2010 Feb;162(2):295-305 - PubMed
  16. Mol Cell Endocrinol. 2010 Jun 30;322(1-2):135-43 - PubMed
  17. J Clin Endocrinol Metab. 2010 Jul;95(7):3260-7 - PubMed
  18. ISRN Endocrinol. 2012;2012:325092 - PubMed
  19. Case Rep Med. 2013;2013:194542 - PubMed
  20. Iran J Ped Hematol Oncol. 2013;3(2):73-7 - PubMed
  21. Z Gesamte Inn Med. 1989 May 15;44(10):300-6 - PubMed
  22. Medicine (Baltimore). 2017 Feb;96(5):e6035 - PubMed
  23. Clin Endocrinol (Oxf). 2017 May;86(5):755-759 - PubMed
  24. Front Immunol. 2017 May 09;8:521 - PubMed
  25. Acta Biochim Pol. 2018;65(1):17-24 - PubMed
  26. Clin Med Insights Case Rep. 2018 Jun 25;11:1179547618781090 - PubMed
  27. Eur Thyroid J. 2018 Aug;7(4):167-186 - PubMed
  28. Postgrad Med J. 1988 Oct;64(756):735-42 - PubMed
  29. Hematol Oncol Clin North Am. 1987 Jun;1(2):261-79 - PubMed
  30. Br J Haematol. 1977 Oct;37(2):173-7 - PubMed
  31. Acta Haematol. 1980;63(4):185-90 - PubMed
  32. South Med J. 1983 Mar;76(3):335-7, 340 - PubMed
  33. N Z Med J. 1981 Mar 11;93(679):143-5 - PubMed
  34. Eur J Endocrinol. 1994 Jun;130(6):565-8 - PubMed
  35. Clin Pediatr (Phila). 1993 Jan;32(1):25-9 - PubMed
  36. Clin Exp Immunol. 1977 Feb;27(2):216-21 - PubMed
  37. J Clin Endocrinol Metab. 1997 Jun;82(6):1727-33 - PubMed
  38. Hepatogastroenterology. 1997 Nov-Dec;44(18):1614-8 - PubMed
  39. Thyroid. 1998 Aug;8(8):727-34 - PubMed
  40. Mil Med. 1978 Aug;143(8):548-51 - PubMed

Publication Types